Zydus Lifesciences, through its joint venture Zydus Sunshine Lifesciences, has inked a deal with Sri Lanka’s Board of Investment to set up a manufacturing plant in Horana. The facility, requiring an investment of over USD 20 million, will focus on oral solid dosages and is expected to start commercial operations by 2028. This move aims to localize medicine production and bolster the company’s footprint in the island nation.
Zydus Lifesciences Commits USD 20 Million to Sri Lankan Manufacturing Facility
Investment of over USD 20 million; manufacturing facility set for 2028 launch in Horana, Sri Lanka.
Reader Takeaway: This JV improves regional supply chain resilience but remains subject to project execution and regulatory milestones.
What just happened
Zydus Sunshine Lifesciences, a joint venture between Zydus Lifesciences and Sunshine Healthcare, has officially entered into an agreement with the Board of Investment (BOI) of Sri Lanka. The project centers on the construction of a pharmaceutical manufacturing plant located in the BOI industrial zone in Horana. The agreement, signed on October 13, 2026, follows the initial announcement of the partnership made in June 2026.
Why this matters
The facility is set to manufacture oral solid dosage forms specifically tailored to the local Sri Lankan market. By shifting to domestic production, the venture aims to reduce reliance on imports and improve the local availability of essential medicines. For shareholders, this represents a deliberate move by Zydus to expand its international operational footprint and secure market share in a new geography.
Investment and operations
The project is structured as a phased investment exceeding USD 20 million. The facility will occupy a site spanning nearly four acres. While the construction phase is now underway, the company has targeted a 2028 commencement date for full commercial operations.
Risks to watch
The primary risk factor for investors is the dependency on regulatory approvals and construction timelines. While 2028 is the target year, any delays in permitting or industrial development could push back revenue generation. Investors should track subsequent filings for updates on project milestones and capital expenditure phases.
What to track next
Watch for further announcements regarding ground-breaking events, the procurement of specific equipment for the oral solid dosage lines, and updates on the regulatory certification of the Horana site.